Department of Pharmaceutical Sciences, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
Proteins. 2011 Jun;79(6):1800-9. doi: 10.1002/prot.23004. Epub 2011 Apr 4.
Dipeptidyl peptidase IV (DPP4) is an important target for the treatment of Type II diabetes mellitus. The crystal structure of DPP4 demonstrates that there are two possible pathways to the active site, a side opening and a β propeller opening. However, it still lacks quantitative evidence to illustrate which pathway is more favorable for inhibitor to enter into or release from the active site. In this study, conventional and steered molecular dynamics simulations were performed to explore the details of inhibitor Q448 release from the active site of DPP4 via the two potential pathways. The comparisons of force and work together with potentials of mean force results suggested that the side opening might be more favorable for the inhibitor to pass through. Moreover, Glu205-Glu206 and Phe357 were recognized as two "key residues" in the active site for inhibitor binding. Accordingly, suggestions for further inhibitor design were provided.
二肽基肽酶 4(DPP4)是治疗 2 型糖尿病的重要靶点。DPP4 的晶体结构表明,存在两种可能的进入活性位点的途径,即侧开口和β 三叶桨式开口。然而,目前仍缺乏定量证据来阐明哪种途径更有利于抑制剂进入或从活性位点释放。在这项研究中,进行了常规和导向分子动力学模拟,以探索抑制剂 Q448 通过两种潜在途径从 DPP4 活性位点释放的细节。力和功的比较以及平均力势结果表明,侧开口可能更有利于抑制剂通过。此外,Glu205-Glu206 和 Phe357 被认为是活性位点中用于抑制剂结合的两个“关键残基”。因此,提供了进一步抑制剂设计的建议。